EUVIMEDEUVIMED entdecken
Crossref

Papillary renal cell carcinoma revisited: impact of the World Health Organization 2022 classification on prognostication

Joung Won Sung, Yong Il Lee, Younjuong Kim, Cheryn Song iD, Ja-Min Park, Sun Young Yoon, Bokyung Ahn, Yong Mee Cho

BJU International · 2025-03 · 135 (3) · 510-516

DOI: 10.1111/bju.16590 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BJU International, online erschienen am 25.11.2024. Verfasst von Joung Won Sung und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Kidney Neoplasms, Carcinoma, Renal Cell. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To investigate the impact of the revised papillary renal cell carcinoma (PRCC) classification and evaluate its validity with regard to oncological outcome stratification. Patients and Methods Identifying 527 patients with PRCC who underwent surgical resection from 1995 to 2022, a tissue microarray was constructed for immunohistochemical and molecular characterisation. Re‐classification according to the World Health Organization (WHO) 2022 criteria and nuclear grading according to the WHO/International Society of Urological Pathologists criteria were done. In addition to the revised subtype, alleged clinicopathological prognosticators were analysed with respect to progression‐free (PFS) and cancer‐specific survival (CSS).

Results

Initially, 247 (46.9%) cases were Type 1, 234 (44.4%) were Type 2, and 46 (8.7%) were papillary not‐otherwise‐specified. According to the revised criteria, 29.9% of Type 1 and 57.7% of Type 2 PRCC cases were re‐classified. Re‐classified from Type 1 included more indolent tumours while from Type 2 PRCC many molecularly defined tumours were newly identified. After re‐classification, still 373 tumours remained with distinct histomorphological features of Type 1 (254 [70%]) and Type 2 (119 [42.2%]) PRCC. Furthermore, significant differences in survival outcomes were obtained when the revised criteria was used particularly for tumours of ≤4 cm. For a median (interquartile range) follow‐up of 79 (38.2–132.8) months, the 5‐year PFS was 97% for Type 1, 80% for Type 2, 75% for transcription factor for immunoglobulin heavy‐chain enhancer 3 ( TFE3 )‐rearranged, and 43.5% for fumarate hydratase‐deficient RCC. No disease progression was observed in patients with papillary renal neoplasm with reverse polarity.

Conclusion

The revised WHO 2022 classification enhanced prognostic accuracy for PRCC particularly for small tumours. Retaining previous subtypes may confer further clinical as well as prognostic value.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney NeoplasmsCarcinoma, Renal CellHumansWorld Health OrganizationMaleFemalePrognosisMiddle AgedAgedAdultRetrospective StudiesAged, 80 and over

Stichwörter der Autor:innen

WHO classificationcarcinomamolecular diagnosispapillaryrenal cell

Autor:innen und Institutionen

  • Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

ORCID-Profile: Cheryn Song

Zitieren

APA

Sung, J. W., Lee, Y. I., Kim, Y., Song, C., Park, J. M., Yoon, S. Y., Ahn, B., & Cho, Y. M. (2025). Papillary renal cell carcinoma revisited: impact of the World Health Organization 2022 classification on prognostication. BJU International, 135(3), 510-516. https://doi.org/10.1111/bju.16590

Vancouver

Sung JW, Lee YI, Kim Y, Song C, Park JM, Yoon SY, et al. Papillary renal cell carcinoma revisited: impact of the World Health Organization 2022 classification on prognostication. BJU International. 2025;135(3):510-516. doi:10.1111/bju.16590

BibTeX
@article{Sung2025,
  author = {Sung, Joung Won and Lee, Yong Il and Kim, Younjuong and Song, Cheryn and Park, Ja-Min and Yoon, Sun Young and Ahn, Bokyung and Cho, Yong Mee},
  title = {Papillary renal cell carcinoma revisited: impact of the World Health Organization 2022 classification on prognostication},
  journal = {BJU International},
  year = {2025},
  volume = {135},
  number = {3},
  pages = {510--516},
  doi = {10.1111/bju.16590}
}
Kostenlos starten →